Pixl Bio
Human iPSC cell models, phenomics and custom research services for pharmaceutical and biotechnology drug discovery teams
Highlights
- New on EvolcAdded 2026-11-08
About Pixl Bio
Pixl Bio supplies human iPSC-derived cell models, CRISPR-edited disease models, high-content Cell Painting and image-based phenomics, and custom research studies with data analysis. Its capabilities can be purchased separately or combined with its experimental platform.
Its customers include biopharma partners and research teams working on drug discovery, toxicology, target validation and mechanism-of-action studies. It provides cell products, imaging and analytics, and fee-based custom study services.
Pixl Bio Ltd is based in Cambridge and was founded in 2011. The company describes its origins as a merger of DefiniGEN and Phenaros and presents Cambridge and Uppsala as its scientific bases.
Product: Human iPSC-derived cell models, CRISPR disease models, high-content imaging and AI phenomics, plus custom research services.
Jobs at Pixl Bio
Leadership
- Jordi Carreras Puigvert · CSO, Co-FounderSource: company website
- Ola Spjuth · CAIO, Co-FounderSource: company website
- Christopher Trummer · CEO, Co-FounderSource: company website
- Morgan Ekmefjord · CTO, Co-FounderSource: company website
More biotech & pharma companies
Plaquetec
Coronary artery disease endotyping and biomarker discovery for drug developers, using in-vivo plaque samplingNew on EvolcPlethora Solutions
Speciality pharma developing and marketing urology treatments, led by an EU-authorised drug for premature ejaculationNew on EvolcPolymodels Hub
AI-powered process modeling and workflow software for pharmaceutical and biopharmaceutical teamsYoung companyNew on EvolcPrecision Cellular Storage
Stem cell storage service for individual customers in the UK and Qatar, formerly known as Virgin Health BankNew on EvolcPrimer Design
Real-time PCR assays and qPCR kits for diagnostic labs, food testing and veterinary useNew on EvolcProkarium
Microbial immunotherapy platform built on a proprietary bacterial strain (ZH9) for solid tumour treatmentsNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Content management
- WebflowHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
CRM & customer data
- HubSpotHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Website resourcedeclared script/iframe or software asset
- Website resourcedeclared script/iframe or software asset
Forms
- Google reCAPTCHAHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- AWSHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Marketing & advertising
- Google AdsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.